Prime Medicine, Inc.: ARK Investment Management LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ARK Investment Management LLC disclosed a stake exceeding 5% in Prime Medicine, Inc. via a Schedule 13G filing with the SEC (accession 0001104659-26-126830). The filing signals that ARK, the asset manager founded by Cathie Wood, has crossed the 5% beneficial ownership threshold that triggers mandatory disclosure for certain institutional investors. The exact share count and percentage were not specified in the headline disclosure. The move marks ARK's expanded bet on Prime Medicine, a gene-editing company developing prime editing therapies. Investors will watch for further 13G amendments or 13D filings for details on the size and intent of the position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
ARK Investment Management LLC, Prime Medicine, Inc.